Exact Sciences Corporation (NASDAQ:EXAS) closed the previous session at $79.95, down by -0.89 or -1.10% lower on its price over the last trading period. Shares of the company have traded -12.56% down in the last 5 days, with the price reaching as high as $91.43 since 11/04/19. The stock however has recovered +2.07% since hitting 5-day low of $78.32. The EXAS stock is -19.92% lower than the $99.82 top value it marked over a period of month. Exact Sciences Corporation (NASDAQ:EXAS) has a 52-week price range of $53.06- $123.99. The stock is 28.11% up year-to-date. Can EXAS go on to record further gains or will the drop below $80.84 be witnessed again in coming days?
In comparison, let’s see recent movement of other stocks the recent users of Yahoo Finance’s stock information-accessing system have also looked at before they searched Exact Sciences Corporation (EXAS). Shares of Veracyte Inc. (NASDAQ:VCYT) changed -$0.68 or a drop of -2.85% to close at $23.14, while the stock of Invacare Corporation (NYSE:IVC) gained nearly 42.71% in the last session to close at price of $11.26. Antares Pharma Inc. (NASDAQ:ATRS) lost -$0.06 in value, or -1.60% to see deals exchanging hands at $3.68 in the last period. Vermillion Inc. (NASDAQ:VRML) gained $0.01 or about 2.01 to see its shares trade at $0.60.
The total number of analysts who have rated EXAS as a buy is 11, with just 0 of 12 recommending it as a Sell. 12 analysts of the 0 rated it as underweight; while 0 advised Hold and a further 1 say the stock is Overweight.
Lets us now look at some key statistics for the company and see what they tell us about its books. Exact Sciences Corporation has a market valuation of $10.47 billion, with its Enterprise Value at $10.17 billion. The enterprise value (EV) is -2.95% off Exact Sciences Corporation’s market cap. Shares traded in the last session stood at 4177149 while the average trading volume is 1.89 million. Insiders own 0.20% of the shares institutions own 88.40% as outstanding shares currently stand at 129.57 million. When we look at the 20-day simple moving average, EXAS is -11.91%, while that moves to -19.10% over its 50-day SMA and the SMA200 is -20.73%.
When we look at the consensus estimate for EXAS shares, we find that Wall Street analysts have given the average target price of $126.55. The earnings estimate for the current quarter is -0.36, lower than the -0.34 expected for the next quarter. The stock has earnings per share estimate ranging between a low of -0.42 and a high of -0.27, with the coefficient variance at -14.03. For this fiscal year, the estimate climbs to 12.00 versus the 12.00 expected for the next year. EXAS has current-year EPS range between a low of -1.68 and a high of -1.53, with the coefficient variance at -2.72.
The company’s trailing 12-month price-to-sales ratio is 14.47. In terms of profitability, the company has a profit margin of -29.80% and a trailing 12-month (ttm) operating margin of -27.30%. The company’s gross margin is 74.30%. EXAS is one of the hottest stocks right now and that shows in its potential upside on returns with a -12.60% ROA for the last 12 months and a return on equity (ROE) of -29.10% over the same period.
For the fiscal quarter ending 12/30/2018, Exact Sciences Corporation had revenue of $229.36M. The earnings per share for the most recent quarter were -0.44. The EPS for the recent quarter beat consensus estimates by $0.05 per share after analysts had predicted -$0.49. EPS posted in 3 out of the last 4 quarters have beaten analysts’ estimates.
The investor community is excited about the EXAS stock, with the Barchart 88% Sell showing that the stock could be headed for a massive downtrend. The stock’s 1-month chart already shows that the stock is -10.27% down and -32.57% lower in the last 3 months. Its 12-month performance is showing the stock trending higher by 8.88%. There might be a slight pullback as $83.45 is the first resistance point and if crossed $86.05 should come in play as the second resistance level. EXAS could see support around 79.37 and will later test the 77.89 support.